Zonisamide (Zonegran(TM)) is a new, broad-spectrum antiepileptic which has demonstrated a high degree of effectiveness in treating both localization-related and generalized epilepsies, as well as progressive myoclonic epilepsy syndromes. The pharmacokinetic profile of zonisamide is particularly favorable, including rapid and full absorption, a long half- life, and relatively low levels of protein binding. Zonisamide has been evaluated in a total of 7 randomized controlled and open-label studies, with clinical efficacy that is equivalent or superior to that of standard antiepileptic drugs such as carbamazepine and valproate. Administered at an adult dosage of 400-600 mg in two divided daily doses, zonisamide has demonstrated a good safety profile in wide clinical use. This new agent is a significant therapeutic advance, expanding the available treatment options for both adults and children with epilepsy.
|Original language||English (US)|
|Number of pages||15|
|Journal||Today's Therapeutic Trends|
|State||Published - Nov 19 1999|